8-K: Rigel Pharmaceuticals Inks Exclusive Olutasidenib Licensing Deal with Kissei in Asia

Rigel Pharmaceuticals has granted Kissei Pharmaceutical exclusive rights to develop and commercialize olutasidenib in Japan, South Korea, and Taiwan, securing an upfront payment and potential future milestones.

Summary

• Rigel Pharmaceuticals has entered into a collaboration and license agreement with Kissei Pharmaceutical for the development and commercialization of olutasidenib in Japan, South Korea, and Taiwan.
• Kissei will have exclusive rights in these territories, while Rigel retains global rights outside of them.
• Rigel will receive a $10 million upfront payment and is eligible for up to $152.5 million in additional milestone payments.
• Rigel will also receive tiered, escalated net sales-based payments for the supply of olutasidenib, ranging from the mid-twenties to the lower thirties percent.
• Kissei will fund and conduct development activities in their territory, while Rigel retains co-exclusive rights for development to support global approvals.
• Rigel will share 50% of Kissei's companion diagnostic development costs in Japan, up to $3 million, which can be credited against future payments.
• Forma Therapeutics, now Novo Nordisk, is entitled to $2.3 million from the upfront payment as part of their previous agreement with Rigel.
• Rigel will supply Kissei with bulk drug product and will receive transfer price payments until the expiration of certain patents, regulatory exclusivity, or ten years after the first commercial sale.
• The agreement can be terminated for various reasons, including breach, bankruptcy, safety concerns, or failure to obtain regulatory approval.
• Kissei can terminate the agreement without cause after four years, with certain notice periods.

Sentiment

Score: 7

Explanation: The document indicates a positive development for Rigel with a new licensing agreement, upfront payment, and potential for future revenue. However, there are also risks and costs associated with the deal, which temper the overall sentiment.

Positives

• The agreement provides Rigel with an upfront payment of $10 million.
• Rigel has the potential to receive an additional $152.5 million in milestone payments.
• Rigel will receive ongoing revenue through tiered, escalated net sales-based payments for the supply of olutasidenib.
• Kissei will fund and conduct development activities in their territory, reducing Rigel's financial burden.
• Rigel retains global rights to commercialize olutasidenib outside of the Kissei Territory.
• The agreement includes a long-term supply arrangement with Kissei.

Negatives

• Rigel is responsible for 50% of Kissei's companion diagnostic development costs in Japan, up to $3 million.
• Forma Therapeutics, now Novo Nordisk, is entitled to $2.3 million from the upfront payment, reducing Rigel's immediate cash inflow.
• The agreement can be terminated by Kissei under certain conditions, potentially impacting future revenue streams.
• The actual receipt of milestone payments and sales-based payments is not guaranteed and depends on the success of olutasidenib.

Risks

• The FDA, EMA, or other regulatory authorities may make adverse decisions regarding olutasidenib.
• Olutasidenib clinical trials may not be predictive of real-world results or of results in subsequent clinical trials.
• There are risks associated with the availability of resources to develop, manufacture, and commercialize olutasidenib.
• Market competition could impact the success of olutasidenib.
• Rigel's partners may not obtain marketing approval for olutasidenib.
• There is no guarantee that any of the milestone payments or product transfer price payments will be paid under these agreements.

Future Outlook

The document includes forward-looking statements regarding Rigel's receipt of payments from Kissei under the License Agreement and the Supply Agreement, but these are subject to risks and uncertainties.

Management Comments

• The document does not contain any direct quotes from management, but it does state that the company has entered into a material definitive agreement.

Industry Context

This agreement reflects a trend in the pharmaceutical industry where companies collaborate to expand the reach of their products into new markets. It is common for companies to license their products to regional partners to leverage their local expertise and resources.

Comparison to Industry Standards

• Licensing agreements with upfront payments and milestone structures are common in the pharmaceutical industry, particularly for drugs in development.
• The tiered royalty structure is also standard, with rates varying based on the stage of development and market potential.
• The agreement with Kissei is similar to other deals where a company grants regional rights to a partner while retaining global rights outside of the licensed territory.
• Comparable deals include those between large pharmaceutical companies and smaller biotech firms, where the smaller firm licenses its drug to the larger firm for commercialization in specific regions.

Stakeholder Impact

• Shareholders may view this agreement positively due to the potential for increased revenue and reduced development costs.
• Employees may see this as a positive development for the company's growth and stability.
• Customers in the Kissei Territory may benefit from the availability of olutasidenib.
• Suppliers may see increased demand for the drug product.
• Creditors may view this as a positive development for the company's financial health.

Next Steps

• Rigel will file the full text of the agreements as an exhibit to their Quarterly Report on Form 10-Q for the fiscal period ending September 30, 2024.
• Kissei will begin development activities for olutasidenib in Japan, South Korea, and Taiwan.
• Rigel will continue to manufacture and supply olutasidenib to Kissei.

Key Dates

Keywords

olutasidenib, Rigel Pharmaceuticals, Kissei Pharmaceutical, licensing agreement, collaboration, drug development, commercialization, milestone payments, supply agreement, Japan, South Korea, Taiwan